Lung cancer drug combo fails to extend survival in major trial

NCT ID NCT00532155

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This large Phase 3 trial tested whether adding aflibercept (a drug that blocks blood vessel growth) to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. Over 900 participants who had already tried one platinum-based treatment were randomly assigned to receive either aflibercept or a placebo, plus docetaxel. The study found that the combination did not improve overall survival compared to chemotherapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aflibercept (a drug that blocks blood vessel growth, combined with chemotherapy docetaxel)
What this could lead to: If it had worked, this could have pointed toward a new treatment option for advanced non-small cell lung cancer after first-line therapy fails.
What could go wrong: This large Phase 3 trial found that adding aflibercept to docetaxel did not improve overall survival compared to placebo. The study is complete, so the results are final and not promising for this combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA NON-SMALL-CELL LUNG

Contacts and locations

Locations

Sanofi-Aventis Administraive Office

Istanbul, Turkey (Türkiye)
Sanofi-Aventis Administrative Office

Bridgewater, New Jersey, 08807, United States
Sanofi-Aventis Administrative Office

Buenos Aires, Argentina
Sanofi-Aventis Administrative Office

Vienna, Austria
Sanofi-Aventis Administrative Office

São Paulo, Brazil
Sanofi-Aventis Administrative Office

Sofia, Bulgaria
Sanofi-Aventis Administrative Office

Laval, Canada
Sanofi-Aventis Administrative Office

Santiago, Chile
Sanofi-Aventis Administrative Office

Shanghai, China
Sanofi-Aventis Administrative Office

Prague, Czechia
Sanofi-Aventis Administrative Office

Tallinn, Estonia
Sanofi-Aventis Administrative Office

Helsinki, Finland
Sanofi-Aventis Administrative Office

Paris, France
Sanofi-Aventis Administrative Office

Berlin, Germany
Sanofi-Aventis Administrative Office

Athens, Greece
Sanofi-Aventis Administrative Office

Causeway Bay, Hong Kong
Sanofi-Aventis Administrative Office

Budapest, Hungary
Sanofi-Aventis Administrative Office

Mumbai, India
Sanofi-Aventis Administrative Office

Milan, Italy
Sanofi-Aventis Administrative Office

Kuala Lumpur, Malaysia
Sanofi-Aventis Administrative Office

Gouda, Netherlands
Sanofi-Aventis Administrative Office

Warsaw, Poland
Sanofi-Aventis Administrative Office

Porto Salvo, Portugal
Sanofi-Aventis Administrative Office

Bucharest, Romania
Sanofi-Aventis Administrative Office

Moscow, Russia
Sanofi-Aventis Administrative Office

Singapore, Singapore
Sanofi-Aventis Administrative Office

Seoul, South Korea
Sanofi-Aventis Administrative Office

Barcelona, Spain
Sanofi-Aventis Administrative Office

Bromma, Sweden
Sanofi-Aventis Administrative Office

Taipei, Taiwan
Sanofi-Aventis Admnistrative Office

Guildford Surrey, United Kingdom
sanofi-aventis Australia & New Zealand administrative office

Macquarie Park, New South Wales, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.